00:07:21 Vickie Danaher So for instance, the new oral semaglutide for obesity is also approved to reduce the risk of cardiovascular events, such as strokes or heart attacks, in patients with cardiovascular disease and obesity
Individual treatment decisions depend on medical history, laboratory testing, medications, risk factors, and provider assessment
Meta-analyses have shown that the amount of weight regained after stopping treatment is typically proportional to the initial weight loss, and lifestyle interventions become increasingly difficult to maintain once the medication is discontinued ( 10 Expanding the use of GLP-1RAs to treat substance use disorders To date, only a limited number of clinical trials have evaluated the effectiveness of GLP-1RAs for substance use disorders, yet initial findings are encouraging
Financing At Weight & Body Solutions, we believe that everyone deserves to look and feel their best without financial stress getting in the way